Here are four treatments that are in development in the biologics space:
GrĂ¼nenthal and Mesoblast entered into a partnership to develop a biologics-based treatment for chronic lower back pain.
NervGen Pharma is planning its clinical development strategy for its compound, NVG-291, in spinal cord injury and multiple sclerosis patients.
Duchenne UK awarded researchers from Minneapolis-based University of Minnesota Medical School $945,000 to advance their work around a stem cell-based therapy to treat Duchenne muscular dystrophy.
Ortho Regenerative Technologies reported a successful pre-investigational drug meeting with the FDA in February and is now preparing for its rotator cuff phase I/II clinical trial.